SuperworthEstablishment Labs profit margin ESTA
Gross, operating and net profit as a share of revenue over the last twelve months, from 2018.
- Net margin, 12 months
- −15.8%
- Operating margin, 12 months
- −7.6%
- Net margin on a year earlier
- +34.1 pts
- Peer median
- 7.3%
Over the twelve months to Jun 30, 2026, Establishment Labs kept −15.8% of its revenue as net profit, with an operating margin of −7.6% and a gross margin of 70.5%.
Five years earlier its net margin was −19.8%.
The median for 10 medical instruments and supplies stocks of a similar size is 7.3%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −24.2% | −18.5% | 69.3% |
| FY2024 | −51.0% | −30.1% | 66.0% |
| FY2023 | −47.5% | −39.4% | 64.8% |
| FY2022 | −46.5% | −24.5% | 65.9% |
| FY2021 | −32.5% | −19.8% | 67.4% |
| FY2020 | −45.0% | −33.0% | 62.0% |
| FY2019 | −42.6% | −34.5% | 61.3% |
| FY2018 | −34.5% | −39.0% | 59.0% |
| FY2017 | n/a | −57.6% | 51.0% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −15.8% | +34.1 pts | −7.6% | |
| Q1 FY26 | −19.1% | +33.3 pts | −12.4% | |
| Q4 FY25 | −24.2% | +26.8 pts | −18.5% | |
| Q3 FY25 | −43.5% | +2.7 pts | −28.1% | |
| Q2 FY25 | −49.9% | +5.1 pts | −35.4% | |
| Q1 FY25 | −52.3% | +0.8 pts | −34.1% | |
| Q4 FY24 | −51.0% | −3.4 pts | −30.1% | |
| Q3 FY24 | −46.1% | −5.8 pts | −34.9% | |
| Q2 FY24 | −55.0% | −20.6 pts | −40.5% | |
| Q1 FY24 | −53.1% | −5.3 pts | −42.2% | |
| Q4 FY23 | −47.5% | −1.0 pts | −39.4% | |
| Q3 FY23 | −40.3% | +9.2 pts | −31.6% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Establishment Labs' size, closest first, today.
| Company | Profit margin |
|---|---|
| ESTAEstablishment Labs | −15.8% |
| LMATLemaitre Vascular | 25.0% |
| INSPInspire Medical Systems | 15.0% |
| UFPTUFP Technologies | 11.4% |
| EYENational Vision | 2.5% |
| CDRECadre | 5.3% |
| BVSBioventus | 9.4% |
| ATRCAtriCure | 1.9% |
| STAAStaar Surgical | 1.1% |
| WRBYWarby Parker | 0.8% |
| IRMDIradimed | 26.7% |
| Peer median | 7.3% |
Where Establishment Labs ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Establishment Labs
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.